AMGN vs STRO · P/E 24, rev $36.75B vs rev $62.0M
Amgen Inc (AMGN) versus Sutro Biopharma (STRO) — a side-by-side from cached financials, not a winner call.
Amgen Inc (AMGN) is a drug manufacturers - general company listed on US.
Sutro Biopharma (STRO) is a biotechnology company listed on NASDAQ.
Latest reported AMGN revenue for 2025-12-31 was $36.75B. Net income was $7.71B. Revenue was up 10.0% from 2024-12-31 to 2025-12-31. AMGN currently screens at market cap $188.67B and trailing P/E 24.3.
Latest reported STRO revenue for 2024-12-31 was $62.0M. Net income was -$227.5M. Revenue was down 59.6% from 2023-12-31 to 2024-12-31. STRO currently screens at market cap $470.8M.
AMGN currently screens at market cap $188.67B and trailing P/E 24.3. STRO currently screens at market cap $470.8M.
Not investment advice. Open the AMGN and STRO stock pages for the full models.
Not investment advice.